Ovalbumin increases macromolecular efflux from the in situ nasal mucosa of allergic hamsters.
The purpose of this study was to determine whether bradykinin mediates ovalbumin-induced increase in macromolecular efflux from the nasal mucosa of ovalbumin-sensitized hamsters in vivo and, if so, whether the L-arginine/nitric oxide biosynthetic pathway transduces, in part, this response. We found that suffusion of ovalbumin onto the in situ nasal mucosa of ovalbumin-sensitized hamsters, but not of controls, elicited a significant time- and concentration-dependent increase in clearance of fluorescein isothiocyanate-labeled dextran (mol mass, 70 kDa; P < 0.05). HOE-140, but not des-Arg9,[Leu8]-bradykinin, and NG-L-arginine methyl ester (L-NAME), but not NG-D-arginine methyl ester, significantly attenuated ovalbumin-induced responses. L-Arginine, but not D-arginine, abolished the effects of L-NAME. L-NAME also significantly attenuated bradykinin-, but not adenosine-induced increase in macromolecular efflux from the in situ nasal mucosa. Overall, these data suggest that ovalbumin increases macromolecular efflux from the in situ nasal mucosa of ovalbumin-sensitized hamsters, in part, by producing bradykinin with subsequent activation of the L-arginine/ nitric oxide biosynthetic pathway.
Gao
X P
XP
Department of Medicine, University of Illinois at Chicago, USA.
Akhter
S R
SR
Rubinstein
I
I
D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000378:metabolism; D001920:Bradykinin / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D006224:Cricetinae; D003911:Dextrans; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005122:Exudates and Transudates / Q000378:metabolism / Q000502:physiology; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives; D008297:Male; D008647:Mesocricetus; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D014663:Nasal Decongestants / Q000494:pharmacology; D009297:Nasal Mucosa / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010047:Ovalbumin / Q000378:metabolism / Q000494:pharmacology*; D010656:Phenylephrine / Q000494:pharmacology; D012130:Respiratory Hypersensitivity / Q000378:metabolism*; D015842:Serine Proteinase Inhibitors / Q000378:metabolism*; D014665:Vasodilator Agents / Q000494:pharmacology
D065168:Bradykinin Receptor Antagonists; D003911:Dextrans; D004791:Enzyme Inhibitors; D014663:Nasal Decongestants; D015842:Serine Proteinase Inhibitors; D014665:Vasodilator Agents; C015219:fluorescein isothiocyanate dextran; D010656:Phenylephrine; D009569:Nitric Oxide; D010047:Ovalbumin; D001120:Arginine; D019001:Nitric Oxide Synthase; D016650:Fluorescein-5-isothiocyanate; D000241:Adenosine; D001920:Bradykinin; D019331:NG-Nitroarginine Methyl Ester